Literature DB >> 21726828

Funding translational work in cell-based therapy.

Mahendra S Rao1.   

Abstract

The cell therapy branch of the regenerative medicine field has been innovative in developing new models of delivery and development and identifying alternative sources of funding. We discuss the implications of these changes for pharmaceutical companies and the opportunities they offer to a new entrepreneur.
Copyright © 2011 Elsevier Inc. All rights reserved.

Mesh：

Year:  2011        PMID： 21726828     DOI： 10.1016/j.stem.2011.06.009

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  5 in total

1.  Value-engineered translation for regenerative medicine: meeting the needs of health systems.

Authors:  Tania Bubela; Christopher McCabe
Journal:  Stem Cells Dev       Date:  2013-12       Impact factor: 3.272

2.  Stem cells and regenerative medicine.

Authors:  Mahendra Rao
Journal:  Stem Cell Res Ther       Date:  2012-07-09       Impact factor: 6.832

3.  High-throughput assessment of mechanical properties of stem cell derived red blood cells, toward cellular downstream processing.

Authors:  Ewa Guzniczak; Maryam Mohammad Zadeh; Fiona Dempsey; Melanie Jimenez; Henry Bock; Graeme Whyte; Nicholas Willoughby; Helen Bridle
Journal:  Sci Rep       Date:  2017-10-31       Impact factor: 4.379

4.  Is belief larger than fact: expectations, optimism and reality for translational stem cell research.

Authors:  Tania Bubela; Matthew D Li; Mohamed Hafez; Mark Bieber; Harold Atkins
Journal:  BMC Med       Date:  2012-11-06       Impact factor: 8.775

5.  Challenges in the translation and commercialization of cell therapies.

Authors:  Brittany P Dodson; Aaron D Levine
Journal:  BMC Biotechnol       Date:  2015-08-07       Impact factor: 2.563
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.